title: Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?
abstract: In the early 1990s, within three years of cloning of endothelin receptors, orally active endothelin receptor antagonists (ERAs) were tested in humans and the first clinical trial of ERA therapy in humans was published in 1995. ERAs were subsequently tested in clinical trials involving heart failure, pulmonary arterial hypertension, resistant arterial hypertension, stroke/subarachnoid hemorrhage and various forms of cancer. The results of most of these trials - except those for pulmonary arterial hypertension and scleroderma-related digital ulcers - were either negative or neutral. Problems with study design, patient selection, drug toxicity, and drug dosing have been used to explain or excuse failures. Currently, a number of pharmaceutical companies who had developed ERAs as drug candidates have discontinued clinical trials or further drug development. Given the problems with using ERAs in clinical medicine, at the Twelfth International Conference on Endothelin in Cambridge, UK, a panel discussion was held by clinicians actively involved in clinical development of ERA therapy in renal disease, systemic and pulmonary arterial hypertension, heart failure, and cancer. This article provides summaries from the panel discussion as well as personal perspectives of the panelists on how to proceed with further clinical testing of ERAs and guidance for researchers and decision makers in clinical drug development on where future research efforts might best be focused.
authors.affiliation: Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA.
authors.forename: Donald E
authors.initials: DE
authors.lastname: Kohan
authors.forename: John G
authors.initials: JG
authors.lastname: Cleland
authors.forename: Lewis J
authors.initials: LJ
authors.lastname: Rubin
authors.forename: Dan
authors.initials: D
authors.lastname: Theodorescu
authors.forename: Matthias
authors.initials: M
authors.lastname: Barton
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods*; D015195:Drug Design; D065128:Endothelin Receptor Antagonists; D065627:Familial Primary Pulmonary Hypertension; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000503:physiopathology; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D018579:Patient Selection; D020521:Stroke / Q000188:drug therapy / Q000503:physiopathology; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D065128:Endothelin Receptor Antagonists